Vakzine Projekt Management GmbH (VPM) announced that the first participant has been enrolled on May 25th in a phase III study to investigate whether the vaccine candidate VPM1002 is effective against respiratory disease like COVID-19 The large-scale study is initially to be carried out at several hospitals in Hanover, Munich, Erfurt and will soon include additional cities. The clinical trial will include healthcare workers which are particularly at risk from the disease. More!
Press release on February 20, 2020: Modified tuberculosis vaccine as a therapy for cancer of the bladder. A therapy with VPM1002 is effective for bladder cancer patients. Please klick here for the whole release!
The pivotal phase III infant vaccine trial was accepted by the African Vaccine Regulatory Forum (AVAREF) for a joint review process. The meeting has taken place from 22-24th of January 2020 in Nairobi, Kenya.
VPM will give a lecture about tuberculosis at the conference "Immunotherapy for infectious diseases" from 05 - 07 October, 2020 in Italy.
The VPM employee Alexandra Hierweger received the Uwe Koch-Gromus-PhD-Promotionspreis 2019 for her PhD thesis with the title 'Influence of influenza A virus infections on the maternal immune system during pregnancy'. The ceremony took place on 6th of December 2019 at the University Medical Center Hamburg-Eppendorf.
VPM will be participant and speaker at the TB vaccine conference in Les Diablerets, Switzerland, taking place from 27 – 29 January 2020.
The priMe Investigator meeting has taken place from 27-28th of November 2019 in Dar es Salaam, Tanzania.
VPM will give a lecture for the TRAIN academy on 7th November 2019 at TWINCORE with the title „ Methods for successful project management - achieving project goals faster and more securer."